New combo therapy aims to beat rare childhood lymphoma

NCT ID NCT07013565

Recruiting now Disease control Sponsor: New York Medical College Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times

Summary

This study tests a new treatment for children, teens, and young adults with a rare type of blood cancer (ALK+ anaplastic large cell lymphoma) that has come back or not responded to standard therapy. The approach combines an immunotherapy drug (nivolumab) with chemotherapy, followed by a stem cell transplant from a donor. The goal is to improve survival while managing side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

New York Medical College
RECRUITING

Valhalla, New York, 10595, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE